文献速递类风湿关节炎其他结缔组织病

简要报告:既往风湿病患者中的癌症免疫治疗:梅奥诊所经验

Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
PubMed 文献 · Arthritis Rheumatol · 2018-02-06

梅奥诊所2011至2016年回顾性病历审查约700例接受免疫检查点抑制剂(ICI)治疗的患者,识别出16例既往风湿病患者,其中6例发生免疫相关不良事件(IRAEs),均经糖皮质激素和停用ICI成功处理,仅少数患者出现原有风湿病复发或其他IRAEs。

要点

  • 16例既往风湿病患者接受ICI治疗,6例发生IRAEs,均经糖皮质激素和停用ICI成功处理。
  • 最常见风湿病为类风湿关节炎(n=5)和风湿性多肌痛(n=5)。
  • 7例在开始ICI时正使用免疫抑制治疗或糖皮质激素治疗风湿病。

核心结论

  • 据作者所知,这是最大的单中心既往风湿病患者接受现代癌症免疫治疗的队列,仅少数患者出现原有风湿病复发或其他IRAEs。

研究设计与样本

  • 回顾性病历审查,纳入2011至2016年在明尼苏达州罗切斯特梅奥诊所接受ICI治疗的全部患者(约700例),通过特定诊断代码识别既往风湿病患者。

主要发现

  • 共识别16例患者(81%女性,中位年龄68.5岁),最常见风湿病为类风湿关节炎(n=5)、风湿性多肌痛(n=5)、舍格伦综合征(n=2)和系统性红斑狼疮(n=2)。
  • 7例在开始ICI时正接受免疫抑制治疗或糖皮质激素治疗风湿病。
  • 主要恶性肿瘤为黑色素瘤(n=10)、肺部肿瘤(n=4)或血液系统肿瘤(n=2),多数病例在其他多种治疗失败后才提供ICI。
  • 6例发生IRAEs,均经糖皮质激素和停用ICI治疗成功。
  • 有无IRAEs的患者在从癌症诊断到免疫治疗的时间、免疫治疗持续时间、年龄或性别方面无显著差异。

关键数值与推荐

  • 既往风湿病患者16例,IRAEs发生6例,均经糖皮质激素和停用ICI成功处理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the risk of rheumatic disease flare and adverse effects in patients with preexisting rheumatic disease who were receiving immune checkpoint inhibitor (ICI) therapy. METHODS: A retrospective medical record review was performed to identify all patients who received ICI therapy at Mayo Clinic in Rochester, Minnesota between 2011 and 2016 (~700 patients). Those with a preexisting rheumatic disease were identified using specific diagnostic codes. RESULTS: Sixteen patients were identified (81% female, median age 68.5 years). The most common rheumatic diseases were rheumatoid arthritis (n = 5), polymyalgia rheumatica (n = 5), Sjögren's syndrome (n = 2), and systemic lupus erythematosus (n = 2). Seven patients were receiving immunosuppressive therapy or glucocorticoids for their rheumatic disease at the time of initiation of the ICI. The primary malignancies were melanoma (n = 10), pulmonary (n = 4), or hematologic (n = 2). In most cases, ICIs were offered only after failure of several other therapies. Immune-related adverse effects (IRAEs) occurred in 6 patients, and all were treated successfully with glucocorticoids and discontinuation of the ICI therapy. There were no significant differences in time from cancer diagnosis to immunotherapy, duration of immunotherapy, age, or sex between the patients with and those without IRAEs. CONCLUSION: To our knowledge, this represents the largest single-center cohort of patients with rheumatic diseases who were exposed to modern cancer immunotherapy. Only a minority of these patients experienced a flare of their preexisting rheumatic disease or any other IRAE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Richter MD, Pinkston O, Kottschade LA, et al. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol. 2018. PMID: 29363290. doi:10.1002/art.40397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。